Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light
of the multitude of recent phase III trials that have failed to meet their primary endpoints …

Radiotherapy (RT) aims to deliver a spatially conformal dose of radiation to tumours while
maximizing the dose sparing to healthy tissues. However, the internal patient anatomy is …

Despite standard of care for glioblastoma, including gross total resection, high-dose
radiation, and dose-limited chemotherapy, this tumor remains one of the most aggressive …

Highlights•As of July 2018, there were 759 ongoing or projected clinical trials for
glioblastoma.•Drug therapies appear compromised by the need to combat tumour …

Background There have been few treatment advances for patients with glioblastoma (GBM)
despite increasing scientific understanding of the disease. While factors such as intrinsic …

Tyrosine kinase inhibitor‐(TKI‐) based therapy revolutionized the overall survival and the
quality of life in non‐small‐cell lung cancer (NSCLC) patients that have epidermal growth …

Therapeutic options for the treatment of glioblastoma remain inadequate despite concerted
research efforts in drug development. Therapeutic failure can result from poor permeability …

Glioblastoma is the most common malignant primary central nervous system tumor and one
of the most debilitating cancers. The prognosis of patients with glioblastoma remains poor …

Simple Summary Although multiple meta-analyses on active specific immunotherapy
treatment for glioblastoma multiforme (GBM) have demonstrated a significant prolongation of …

Glioblastoma multiforme (GBM) is an aggressive brain cancer showing poor prognosis.
Currently, treatment methods of GBM are limited with adverse outcomes and low survival …